Low Omentin-1 Levels Are Related with Clinical and Metabolic Parameters in Obese Children

Abstract

Objective:

This is the first clinical study evaluating the relation of serum omentin 1 levels with anthropometric and metabolic parameters in obese children with a particular interest to identify the possible role of omentin 1 in childhood obesity and related metabolic disturbances.

Subjects-Methods:

The study included obese children with a body mass index (BMI)>95^th percentile and healthy children with a BMI<85^th percentile. The healthy and obese subjects had similar age and gender distribution. Glucose, insulin, lipid profile, and omentin 1 levels were measured to evaluate the metabolic parameters.

Results:

49 obese children who applied to our department with complaint of weight gain and 30 healthy age and sex matched subjects were enrolled. In obese children BMI, body mass index-standard deviation score (BMI-SDS), systolic blood pressure (SBP), diastolic blood pressure (DBP), mid-arm circumference (MAC), triceps skin fold (TSF), waist circumference (WC), homeostasis model assessment-insulin resistance (HOMA-IR), serum insulin, and triglyceride levels were higher whereas omentin-1 levels were lower than control subjects (p<0.05). In the obese group, omentin 1 level was negatively correlated with BMI, insulin, HOMA-IR, and WC, while no significant correlation was observed with other parameters (p>0.05). Additionally, although statistically insignificant, patients with IR (n=31) had lower omentin-1 levels compared to obese children without IR (n=18).

Conclusion:

Our data indicates that serum omentin 1 levels are i) lower in obese children and ii) negatively correlated with BMI, WC, HOMA-IR and insulin levels suggesting that omentin 1 might be a biomarker for metabolic dysfunction also in childhood and adolescence. Lower omentin 1 levels tended to be associated with insulin resistance however this association failed to reach statistical significance. Further studies in larger populations are needed to better-define the relation of omentin 1 and insulin resistance in obese children.

Key words

obesity - omentin-1 - childhood - insulin resistance

• References

• 1 Huang JS, Barlow SE, Quiros-Tejeira RE et al. The NASPGHAN Obesity Task Force. Consensus Statement: Childhood Obesity for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr 2012; 56: 99-109
• 2 Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887
• 3 Lago F, Gomez R, Gomez-Reino JJ et al. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci 2009; 34: 500-510
• 4 Van Harmelen V, Reynisdottir S, Eriksson P et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-917
• 5 Whitehead JP, Richards AA, Hickman IJ et al. Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280
• 6 Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078-1081
• 7 Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41
• 8 Krusinova E, Pelikanova T. Fatty acid binding proteins in adipose tissue: a promising link between metabolic syndrome and atherosclerosis?. Diabetes Res Clin Pract 2008; 82: S127-S134
• 9 Alessi MC, Peiretti F, Morange P et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867
• 10 Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850
• 11 Auguet T, Quintero Y, Riesco D et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60
• 12 Ramanjaneya M, Chen J, Brown JE et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 3169-3180
• 13 Komiya T, Tanigawa Y, Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal paneth cells in mice. Biochem Biophys Res Commun 1998; 251: 759-762
• 14 Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-E1261
• 15 de Souza Batista CM, Yang RZ, Lee MJ et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661
• 16 Elbein SC, Hoffman MD, Teng K et al. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 1999; 48: 1175-1182
• 17 Hanson RL, Ehm MG, Pettitt DJ et al. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet 1998; 63: 1130-1138
• 18 Vionnet N, Hani EH, Dupont S et al. Genome wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000; 67: 1470-1480
• 19 Wiltshire S, Hattersley AT, Hitman GA et al. A genome wide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 2001; 69: 553-569
• 20 Prats-Puig A, Bassols J, Bargalló E et al. Toward an early marker of metabolic dysfunction: omentin-1 in prepubertal children. Obesity (Silver Spring) 2011; 19: 1905-1907
• 21 Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; 246: 1-190
• 22 Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51: 170-179
• 23 American Academy of Pediatrics . National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 525-584
• 24 Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
• 25 Valerio G, Licenziati MR, Iannuzzi A et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 2006; 16: 279-284
• 26 Rosner B, Prineas RJ, Loggie JM et al. Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 1993; 123: 871-886
• 27 Shibata R, Ouchi N, Takahashi R et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4: 37
• 28 Ouchi N, Parker JL, Lugus JJ et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
• 29 El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28: 1194-1200
• 30 Tan BK, Adya R, Farhatullah S et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-880
• 31 Moreno-Navarrete JM, Catalán V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 9: 7-27